Please assess the completion status of the following clinical trial:

Trial Title: Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of CF~2. Patients aged 18 - 65 years of age who can give informed consent~3. FEV1 \>25% or \<75% predicted (in keeping with Cayston® license)~4. Admitted to the Liverpool Heart \& Chest Hospital with an exacerbation of CF pulmonary disease~5. Presence of PA in lower respiratory tract cultures in the 6 months prior~Exclusion Criteria:~1. Documented allergy to beta-lactam antibiotics or IV Colistin~2. Growth of Burkholderia Cepacia Complex (BCC) within 2 years~3. Pregnancy~4. Previous organ transplant~5. Receiving other clinical trial medication~6. Already prescribed regular Cayston®

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AZLI then Standard Care (Type: EXPERIMENTAL): Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
- Standard Care then AZLI (Type: ACTIVE_COMPARATOR): Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI

Based on this trial design, predict the completion outcome and termination type (if applicable).